1. Home
  2. Studies
  3. Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison
IW-Trends No. 1 9. February 2022 Jasmina Kirchhoff Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

Download PDF
An International Comparison
IW-Trends No. 1 9. February 2022 Jasmina Kirchhoff

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Jasmina Kirchhoff German Economic Institute (IW) German Economic Institute (IW)

The Corona pandemic has led to increasing demands for the reshoring of pharmaceutical production back to Germany. A strategic dependence on non-European active ingredient and drug manufacturers is cited as an argument.

However, the German pharmaceutical industry sources most of its medicinal and chemical inputs either domestically or from other European countries. A similarly regional supply structure is to be found in the pharmaceutical and chemical sectors of those countries which supply the majority of intermediate inputs to Germany’s pharmaceutical industry, with those from China and India playing only a subordinate role. There is thus no evidence that German pharmaceutical production is predominantly dependent on these two Asian nations. However, since intermediate inputs are recorded by value, and prices for generic medicines and their active ingredients are much lower than those for innovative products, it is possible that despite China's small share of intermediate input purchases there may be a dependency in the case of certain individual generics. Nonetheless, a strategic boost to pharmaceutical production in Germany is scarcely to be achieved by expanding generic production. What is needed is rather a well-coordinated package of policy measures designed to encourage locally based firms to maintain and make long-term investments in their domestic production facilities and to promote the development of new innovative production. Such a course also pays off in terms of security of supply, since the patented innovative medicines of today are the generics of tomorrow.

Content element with id 10503
Download PDF
An International Comparison
IW-Trends No. 1 9. February 2022 Jasmina Kirchhoff

Where the German Pharmaceutical Industry Sources its Intermediate Inputs: An International Comparison

Jasmina Kirchhoff German Economic Institute (IW) German Economic Institute (IW)

More about this topic

More about this topic

Read the article
Unzufriedener Chef im Gespräch mit seinen Kollegen bei einer Besprechung im Büro.
IW-Report No. 48 10. November 2026 Martin Beznoska

Public Preferences Regarding Government Spending and Taxes

This study examines public preferences for government spending and taxation using a fully randomised paired conjoint experiment in the 2025 IW-Population-Survey.

Martin Beznoska IW

Read the article
IW-Report No. 41 12. October 2026 Björn Kauder

A Comparison of Public Revenues Across the Federal States

To ensure equivalent living conditions, the federal government influences the revenues of the states and municipalities. Under the fiscal equalization system, financially weak states receive surpluses in the distribution of sales tax revenues, while financially strong states must accept shortfalls.

Björn Kauder IW

More about this topic

Content element with id 9713